Drugs / KAI-9803
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00093197 | Sep 2004 → Oct 2006 | myocardial infarction | KAI Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00785954 | Nov 2008 → Jul 2010 | myocardial infarction | KAI Pharmaceuticals | Completed | Missed primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-05-13 | Bristol-Myers Squibb | Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease bms.com ↗ |
| 2007-02-08 | Daiichi Sankyo | DAIICHI SANKYO returns development rights of KAI-9803 daiichisankyo.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KAI-9803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00785954 ↗ |
| Action | Inhibit | “KAI-9803 is a selective inhibitor of delta PKC.” NCT00093197 ↗ |
| Route | Intravenous | “by intravenous infusion initiated before PCI and continued for ∼2.5 h” PMID 24796339 ↗ May 2014 |